Opportunity Information: Apply for PAR 12 260
Apply for PAR 12 260
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Lymphatics in Health and Disease in the Digestive, Cardiovascular and Pulmonary Systems (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research.
- This funding opportunity was created on Aug 8, 2012 and posted on Aug 8, 2012.
- Applicants must submit their applications by Sep 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $125,000.00 in funding.
- Eligible applicants include: County governments State governments Public housing authorities/Indian housing authorities Private institutions of higher education Native American tribal governments (Federally recognized) Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Small businesses Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity PAR-12-260, titled "Lymphatics in Health and Disease in the Digestive, Cardiovascular and Pulmonary Systems (R21)," is an exploratory/developmental grant program designed to spark early-stage, high-impact research on how lymphatic vessels function in normal physiology and how they contribute to disease processes in major organ systems. The central aim is to encourage innovative projects that clarify what lymphatic vessels do in the digestive, cardiovascular, and pulmonary systems, how their structure and function are regulated locally within specific tissues, and how lymphatic dysfunction can alter organ performance, worsen disease, or influence recovery. The announcement also highlights interest in lymphatics as they relate to resolution of thromboembolic events, as well as inflammation and immune responses in these disease contexts, while making an important boundary clear: applications that primarily focus on immune mechanisms as the main scientific thrust are not considered responsive. In other words, immune and inflammatory pathways can be part of the story, but the lymphatic vessel biology itself needs to be the primary focus.
This FOA uses the NIH R21 mechanism, which is built for exploratory work where the goal is to open up a new line of inquiry, test a novel concept, or generate key preliminary data rather than to complete a mature, fully developed research program. In practical terms, the R21 format is a better fit for studies that are hypothesis-generating, method-developing, or designed to establish feasibility in emerging areas of lymphatic research within these organ systems. The award information provided indicates an award ceiling of $125,000, and there is no cost sharing or matching requirement, which reduces the burden on applicants and makes it easier to propose focused, high-yield aims.
From a scientific scope standpoint, the opportunity is centered on lymphatic vessel physiology and pathophysiology in the context of digestion, cardiopulmonary function, vascular disease, and related complications. That includes understanding the factors that shape "functional anatomy" of lymphatics in specific tissues, meaning not just where vessels are located, but how their architecture, permeability, pumping behavior, and fluid handling are tuned to the needs of an organ at baseline and during disease. The FOA is also interested in mechanistic links between altered lymphatic function and downstream effects on organ function, which could include how disrupted lymph drainage, impaired vessel remodeling, or abnormal lymphatic contractility contributes to tissue edema, changes in local biochemical signaling, altered lipid handling in the gut, or impaired recovery after injury. It explicitly calls out thromboembolic event resolution as an area of interest, pointing to the broader clinical relevance of lymphatic function in clearing inflammatory mediators, interstitial fluids, and possibly influencing the tissue environment in ways that affect clot resolution and healing.
The opportunity is categorized under NIH research areas that include cardiovascular diseases (CFDA 93.837), lung diseases (93.838), blood diseases and resources (93.839), and diabetes/digestive/kidney diseases extramural research (93.847). That spread signals an intentionally cross-cutting program that sits at the intersection of multiple NIH mission areas, reflecting the idea that lymphatic vessels are not a niche topic but a foundational system influencing many disease pathways across organs. Even though lymphatics are often discussed in relation to immunity, this FOA is careful to steer applicants toward lymphatic vessel biology as the lead topic, such as vessel development, maintenance, remodeling, drainage capacity, transport properties, tissue-specific regulation, and how those attributes change with disease and in turn reshape organ function.
Eligibility is broad and includes a wide range of domestic U.S. organizations and governmental entities, such as state and local governments, tribal governments and organizations, public and private institutions of higher education, independent school districts, public housing authorities, nonprofits (including both 501(c)(3) and certain non-501(c)(3) organizations), and for-profit organizations (other than small businesses are explicitly listed, and small businesses are also eligible). The FOA also makes it clear that foreign participation is allowed: non-U.S. (foreign) institutions may apply, non-domestic components of U.S. organizations may apply, and foreign components are permitted as defined by NIH policy. Additional eligible applicant types listed include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, U.S. territories or possessions, and certain regional organizations. This breadth is meant to bring in diverse expertise, including institutions with specialized capabilities in imaging, vascular biology, organ physiology, biomaterials, microfluidics, translational models, or clinical partnerships relevant to digestive and cardiopulmonary diseases.
Administratively, the opportunity is a discretionary grant with a posted and creation date of August 8, 2012. The original and current closing date listed is September 7, 2013, with an archive date of October 8, 2013, meaning this specific announcement is now historical rather than open for new submissions under that exact posting. The sponsoring agency is the National Institutes of Health. For applicants or readers seeking the full announcement text, the FOA provides a link to the NIH Grants Guide page (http://grants.nih.gov/grants/guide/pa-files/PAR-12-260.html) and includes contact directions through the NIH Office of Extramural Research webmaster for access or linking issues.
Taken together, this FOA is best understood as an NIH call for early, creative research projects that will clarify how lymphatic vessels shape disease and recovery in the gut, heart and vasculature, and lungs. It invites investigators to look closely at tissue-specific lymphatic structure and function, identify the drivers of lymphatic changes in disease, and map how those changes translate into clinically meaningful outcomes, while keeping the main emphasis on lymphatic vessel physiology and pathology rather than immune system mechanisms as the primary research centerpiece.
FAQs: NIH PAR-12-260 - Lymphatics in Health and Disease in the Digestive, Cardiovascular and Pulmonary Systems (R21)
What is PAR-12-260?
PAR-12-260 is an NIH Funding Opportunity Announcement (FOA) titled "Lymphatics in Health and Disease in the Digestive, Cardiovascular and Pulmonary Systems (R21)." It supports exploratory, early-stage research on lymphatic vessel biology in the digestive, cardiovascular, and pulmonary systems, with a focus on how lymphatics function in health and how lymphatic dysfunction contributes to disease and recovery.
What is the main goal of this funding opportunity?
The central goal is to encourage innovative, high-impact projects that clarify what lymphatic vessels do in key organ systems (gut, cardiovascular system, lungs), how their structure and function are regulated within specific tissues, and how lymphatic dysfunction can alter organ performance, worsen disease, or influence recovery.
What grant mechanism does this FOA use?
This FOA uses the NIH R21 mechanism, which is intended for exploratory/developmental research. It is designed to help launch new lines of investigation, test novel concepts, develop methods, or generate feasibility data rather than complete a mature, fully developed research program.
What type of research is the R21 mechanism best suited for under this FOA?
Based on the FOA description, the R21 format is a strong fit for hypothesis-generating projects, method development, and feasibility studies in emerging areas of lymphatic research relevant to digestive, cardiovascular, and pulmonary systems.
What scientific areas are considered responsive to the FOA?
Responsive projects are centered on lymphatic vessel physiology and pathophysiology in digestion, cardiopulmonary function, vascular disease, and related complications. The FOA emphasizes understanding tissue-specific lymphatic "functional anatomy" and the mechanistic links between altered lymphatic function and downstream effects on organ function.
What does the FOA mean by tissue-specific "functional anatomy" of lymphatics?
In this FOA, "functional anatomy" refers to more than lymphatic vessel location. It includes how lymphatic architecture, permeability, pumping behavior, and fluid handling are tuned to the needs of a specific organ in normal conditions and how these properties change during disease.
What organ systems are specifically highlighted?
The FOA specifically highlights lymphatic biology in the digestive system, the cardiovascular/vascular system, and the pulmonary system.
Does the FOA encourage research that connects lymphatic dysfunction to organ-level outcomes?
Yes. A key emphasis is on mechanistic links between lymphatic dysfunction and organ performance, disease severity, and recovery. Examples mentioned include effects related to disrupted lymph drainage, impaired remodeling, abnormal contractility, tissue edema, altered biochemical signaling, altered lipid handling in the gut, and impaired recovery after injury.
Is thromboembolic event resolution part of the FOA's interests?
Yes. The FOA explicitly highlights interest in lymphatics as they relate to resolution of thromboembolic events, reflecting clinical relevance in how lymphatic function may influence clearance of interstitial fluid, inflammatory mediators, and the broader tissue environment involved in clot resolution and healing.
Are inflammation and immune responses allowed topics under this FOA?
Inflammation and immune responses can be included as part of the broader disease context, but the FOA sets a boundary: applications primarily focused on immune mechanisms as the main scientific thrust are not considered responsive. Lymphatic vessel biology needs to be the primary focus.
What does "not considered responsive" mean in this context?
Based on the FOA description, it means proposals that make immune mechanisms the central focus (rather than lymphatic vessel biology) do not fit the stated scope for this opportunity.
What kinds of lymphatic biology topics are emphasized?
The FOA steers applicants toward lymphatic vessel biology as the lead topic, including vessel development, maintenance, remodeling, drainage capacity, transport properties, tissue-specific regulation, and how these attributes change with disease and reshape organ function.
What is the award ceiling listed for this opportunity?
The FOA information provided lists an award ceiling of $125,000.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Which NIH mission areas or categories are associated with this FOA?
The opportunity is categorized under NIH research areas including cardiovascular diseases (CFDA 93.837), lung diseases (93.838), blood diseases and resources (93.839), and diabetes/digestive/kidney diseases extramural research (93.847). This signals a cross-cutting program spanning multiple NIH mission areas.
Who is eligible to apply?
Eligibility is broad and includes many domestic U.S. organizations and governmental entities such as state and local governments, tribal governments and organizations, public and private institutions of higher education, independent school districts, public housing authorities, nonprofits (including 501(c)(3) and certain non-501(c)(3) organizations), and for-profit organizations. Small businesses are also listed as eligible.
Are minority-serving institutions and community-based organizations included in the eligible applicant types?
Yes. The FOA lists eligible types that include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, and faith-based or community-based organizations.
Are U.S. territories and regional organizations eligible?
Yes. The eligible applicant types listed include U.S. territories or possessions and certain regional organizations.
Is foreign participation allowed?
Yes. The FOA states that non-U.S. (foreign) institutions may apply, non-domestic components of U.S. organizations may apply, and foreign components are permitted as defined by NIH policy.
Who is the sponsoring agency?
The sponsoring agency for this FOA is the National Institutes of Health (NIH).
What is the administrative status of this FOA (open or historical)?
Based on the dates provided, this specific FOA posting is historical. It has a closing date of September 7, 2013 and an archive date of October 8, 2013, indicating it is not currently open for new submissions under that exact announcement.
What are the key dates listed for PAR-12-260?
The posted/creation date is August 8, 2012. The closing date listed is September 7, 2013. The archive date is October 8, 2013.
Where can someone find the full FOA text?
The FOA references the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-12-260.html.
What should someone do if they have trouble accessing or linking to the announcement?
The FOA notes contact directions through the NIH Office of Extramural Research webmaster for access or linking issues.
How should an applicant frame a project to align with the FOA's intent?
Based on the description provided, projects should keep lymphatic vessel physiology/pathology as the primary focus, emphasize innovation and early-stage exploration appropriate for an R21, and connect tissue-specific lymphatic structure and function to organ-level outcomes in digestive, cardiovascular/vascular, or pulmonary disease contexts.
What is the overall "big picture" purpose of this program?
This FOA is an NIH call for early, creative research to clarify how lymphatic vessels shape disease and recovery in the gut, heart/vasculature, and lungs, while avoiding proposals where immune mechanisms are the primary centerpiece rather than lymphatic vessel biology.
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Cultural Landscape Studies
Previous opportunity: Lymphatics in Health and Disease in the Digestive, Urinary, Cardiovascular and Pulmonary Systems (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 12 260
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 12 260) also looked into and applied for these:
| Funding Opportunity |
|---|
| Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK (R01) Apply for PAR 12 265 Funding Number: PAR 12 265 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Assessment, Serial Evaluation and Subsequent Sequelae of Acute Kidney Injury (ASSESS AKI) Study (U01) Apply for RFA DK 12 509 Funding Number: RFA DK 12 509 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Pilot Studies of Candidate Therapies for Chronic Kidney Disease (CKD) (U01) Apply for RFA DK 12 016 Funding Number: RFA DK 12 016 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Expansion of Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) (U01) Apply for RFA DK 12 017 Funding Number: RFA DK 12 017 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Study (U01) Apply for RFA DK 12 508 Funding Number: RFA DK 12 508 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Advancing Clinical Research in Primary Glomerular Diseases (UM1) Apply for RFA DK 12 014 Funding Number: RFA DK 12 014 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Novel Interventions to Reduce Morbidity and Mortality of Hemodialysis Patients Safety and Other Early Phase Studies (U01) Apply for RFA DK 12 010 Funding Number: RFA DK 12 010 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Multidisciplinary K12 Urologic Research (KURe) Career Development Program Apply for RFA DK 12 013 Funding Number: RFA DK 12 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $600,000 |
| Limited Competition Small Grant Program for NIDDK K01/K08/K23 Recipients (R03) Apply for PAR 12 285 Funding Number: PAR 12 285 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $50,000 |
| George M. OBrien Urology Cooperative Research Centers Program (U54) Apply for RFA DK 12 009 Funding Number: RFA DK 12 009 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $650,000 |
| Ancillary Studies of Acute Kidney Injury, Chronic Kidney Disease, and End Stage Renal Disease Accessing Information from Clinical Trials, Epidemiological Studies, and Databases (R01) Apply for PA 12 299 Funding Number: PA 12 299 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Early Stage Pharmacological Validation of Novel Targets and Accompanying Pre Therapeutic Leads for Diseases of Interest to the NIDDK (R01) Apply for PAR 13 007 Funding Number: PAR 13 007 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $500,000 |
| New Directions in Hematology Research (SHINE II) (R01) Apply for PAS 13 006 Funding Number: PAS 13 006 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Limited Competition Data Coordinating Center for The Environmental Determinants of Diabetes in the Young (TEDDY) Study (UC4) Apply for RFA DK 12 510 Funding Number: RFA DK 12 510 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3) Apply for PAR 13 013 Funding Number: PAR 13 013 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Developmental Centers for Interdisciplinary Research in Benign Urology (P20) Apply for RFA DK 12 022 Funding Number: RFA DK 12 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| Nociceptive GenitoUrinary Development Molecular Anatomy Projects (nGUDMAP) (U01) Apply for RFA DK 12 024 Funding Number: RFA DK 12 024 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3) Apply for PAR 13 028 Funding Number: PAR 13 028 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Stimulating Hematology Investigation New Endeavors (SHINE) (R01) Apply for PAS 13 031 Funding Number: PAS 13 031 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Urologic Chronic Pelvic Pain Syndrome (UCPPS) Research (R01) Apply for RFA DK 12 025 Funding Number: RFA DK 12 025 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 12 260", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
